USO 25035

A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17, D763QC00001)

Disease Types: Lung Cancer Research

Eligibility Requirements:

• Documented Stage IIIB, IIIC, or Stage IV non-squamous NSCLC
without AGA at the time of randomization
• Must have negative test results for EGFR, ALK, ROS1 genomic alterations
• No known tumor genomic alterations in NTRK, BRAF, RET, MET exon 14
skipping, KRAS G12C, HER2 or any AGA with approved targeted tx
• KRAS mutations, with exception of G12C, are eligible
• Radiographic PD on/after most recent tx for adv/met NSCLC
• 1-2 prior lines of tx with plt-based chemo + anti-PD-(L)1 combined or
sequentially (in any order)
• Prior tx with docetaxel excluded
• Prior tx with any anti-TROP2 agent excluded
• Must provide FFPE tumor sample for assessment of TROP2
• Spinal cord compression or brain metastases excluded
• If asymptomatic, stable, and without corticosteroids or anticonvulsants for
at least 7 days prior to randomization are eligible
• At least 1 measurable lesion per RECIST v1.1
For more infomation on this trial CLICK HERE .

Available at:

• Chesapeake
• Hampton (CarePlex)
• Newport News (Port Warwick III)
• Norfolk (Brock Cancer Center)
• Virginia Beach (Princess Anne)
• Williamsburg